美國馬裡蘭州羅克維爾市和中國蘇州2026年4月22日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣布，公司三個重點品種的六項臨床研究入選2026年美國臨床腫瘤學會（ASCO）年會，其中三項獲快速口頭報告。這三個重點品種分別為中國首個獲批上市的第三代BCR-ABL抑制劑奧雷巴替尼（商品名：耐立克^®）、中國首個獲批上市的國產原創Bcl-2選擇性抑制劑利沙托克拉（商品名：利生妥^®）和MDM2-p53抑制劑Alrizomadlin（APG-115）。

一年一度的ASCO年會是全球腫瘤領域最重要、最權威的學術交流盛會，將展示當前國際最前沿的臨床腫瘤學科研成果和腫瘤治療技術。本屆ASCO年會將於5月29日至6月2日（美國當地時間）在芝加哥McCormick會議中心以線上線下結合的形式舉辦。

亞盛醫藥首席醫學官翟一帆博士表示：「這將是亞盛醫藥連續第九年亮相ASCO年會，很高興能夠又一次站在這一國際頂尖學術舞台展示公司的全球創新與研發實力。今年，公司在研品種有多項研究入選，其中三項研究獲快速口頭報告，再次印證了國際學術界對公司原研品種臨床價值的高度認可。我們期待在會議期間為大家分享更為詳實的數據，並繼續加速全球臨床開發進程，早日為患者帶來更多治療選擇。」

亞盛醫藥將在本屆ASCO年會展示的臨床研究進展包括：

快速口頭報告

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
奧雷巴替尼（HQP1351）聯合貝林妥歐單抗治療淋系急變期慢性髓細胞白血病（CML-LBP）或費城染色體陽性B細胞前體急性淋巴細胞白血病（Ph+ BCP-ALL）患者
摘要編號：6513
展示形式：快速口頭報告
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年5月30日 13:15–14:45（美國中部時間）
2026年5月31日 凌晨2:15–3:45（北京時間）
第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
奧雷巴替尼（HQP1351）二線治療慢性期慢性髓細胞白血病（CP-CML）患者的最新療效和安全性數據
摘要編號：6510
展示形式：快速口頭報告
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年5月30日 13:15–14:45（美國中部時間）
2026年5月31日 凌晨2:15–3:45（北京時間）
第一作者：黎緯明教授，華中科技大學同濟醫學院附屬協和醫院血液科

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Alrizomadlin（APG-115）單藥或聯合利沙托克拉（APG-2575）治療復發/轉移性橫紋肌肉瘤（RMS）或其他軟組織肉瘤（STSs）兒童患者
摘要編號：10012
展示形式：快速口頭報告
分會場標題：兒童腫瘤II（Pediatric Oncology II）
報告時間：
2026年5月30日 8:00–9:30（美國中部時間）
2026年5月30日 21:00–22:30（北京時間）
第一作者：張翼鷟教授，中山大學腫瘤防治中心兒童腫瘤科，華南腫瘤學國家重點實驗室，腫瘤醫學協同創新中心

壁報展示

Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
奧雷巴替尼（HQP1351）治療琥珀酸脫氫酶缺陷型（SDH-）腫瘤患者的最新臨床和轉化研究結果
摘要編號：11539
展示形式：壁報展示
分會場標題：肉瘤（Sarcoma）
報告時間：
2026年6月1日 13:30–16:30（美國中部時間）
2026年6月2日 凌晨2:30–5:30（北京時間）
第一作者：邱海波教授，中山大學腫瘤防治中心，華南腫瘤學國家重點實驗室，腫瘤醫學協同創新中心

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
奧雷巴替尼（HQP1351）治療慢性期慢性髓細胞白血病患者的III期臨床研究：正在進行中的POLARIS-2試驗
摘要編號：TPS6608
展示形式：壁報展示
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年6月1日 9:00–12:00（美國中部時間）
2026年6月1日 22:00–次日凌晨1:00（北京時間）
第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球多中心、開放性、隨機、III期注冊臨床研究：正在進行中的GLORA試驗
摘要編號：TPS7101
展示形式：壁報展示
分會場標題：血液系統惡性腫瘤——淋巴瘤和慢性淋巴細胞白血病（Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia）
報告時間：
2026年6月1日 9:00–12:00（美國中部時間）
2026年6月1日 22:00–次日凌晨1:00（北京時間）
第一作者：Matthew Steven Davids, MD，美國丹娜法伯癌症研究院

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球范圍內進行知識產權布局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物制藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關系。如需了解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格注冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT, 佳泰莱^®), next-generation selective RET inhibitor lunbotinib fumarate (A400/EP0031, 宁泰莱^®[1]) and novel ADC SKB500. The abstracts for these studies will be published on the ASCO official website on May 21, 2026, local time.

Detailed information on the studies selected for 2026 ASCO is as follows:

Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 study
Presentation Type: Oral
Abstract Number: 8506
Session Date and Time: May 29, 3:12 PM-3:24 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC)
Presentation Type: Oral
Abstract Number: 8505
Session Date and Time: May 29, 2:36 PM-2:48 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors
Presentation Type: Rapid oral
Abstract Number: 3011
Session Date and Time: June 2, 9:57 AM-10:03 AM CDT | Molecularly Targeted Agents and Tumor Biology

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting);2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About A400/EP0031

A400/EP0031 novel next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of A400/EP0031 has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, A400/EP0031 was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive NSCLC.

About SKB500

SKB500, a novel, proprietary ADC developed via the OptiDC™ platform, is designed to leverage specific target biology through a validated target combined with a differentiated payload-linker strategy. In preclinical investigations, SKB500 demonstrated a favorable therapeutic window with robust efficacy and manageable safety profiles across multiple advanced solid tumors.

Currently, a Phase II exploratory study of SKB500 in combination with immunotherapy with or without chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is ongoing in China.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

成都2026年4月22日 /美通社/ -- 2026年美國臨床腫瘤學會(ASCO)年會將於5月29日至6月2日在美國芝加哥舉行。四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)將在本次大會公佈TROP2 ADC蘆康沙妥珠單抗(sac-TMT，佳泰萊^®)、下一代選擇性RET抑制劑富馬酸侖博替尼(A400/EP0031，寧泰萊^®[1])以及新型ADC SKB500的三項臨床研究結果，相關研究摘要全文將於當地時間2026年5月21日發佈在 ASCO 官方網站上。

2026 ASCO展示的臨床研究成果具體包括：

標題：蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗一線治療PD-L1陽性晚期非小細胞肺癌(NSCLC)：隨機、對照III期研究(OptiTROP-Lung05)結果
展示形式：口頭報告
摘要#：8506
會議日期和時間：當地時間5月29日15:12-15:24 | 肺癌-轉移性非小細胞

標題：下一代選擇性RET抑制劑(SRI)富馬酸侖博替尼(A400/EP0031)用於治療晚期RET融合陽性非小細胞肺癌(NSCLC)患者的關鍵II期研究的療效與安全性
展示形式：口頭報告
摘要#：8505
會議日期和時間：當地時間5月29日14:36-14:48 | 肺癌-轉移性非小細胞

標題：一項評估SKB500治療局部晚期或轉移性實體瘤患者的開放標籤、首次人體研究
展示形式：快速口頭報告
摘要#：3011
會議日期和時間：當地時間6月2日9:57-10:03 | 分子靶向藥物與腫瘤生物學

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)
作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主智慧財產權的新型TROP2 ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單抗沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑載荷pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性TNBC；2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的HR+/HER2- (IHC 0、IHC 1+或IHC 2+/ISH-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床意義上的獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。目前，科倫博泰已在中國開展9項註冊性臨床研究。默沙東已佈局17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於富馬酸侖博替尼(A400/EP0031)(寧泰萊^®[1] )
A400/EP0031是一款新型下一代選擇性RET抑制劑，開發用於治療NSCLC、甲狀腺髓樣瘤(MTC)以及其他RET變異的實體瘤。A400/EP0031用於治療RET融合陽性的局部晚期或轉移性NSCLC成人患者的新藥上市申請(NDA)已獲中國國家藥品監督管理局藥品評審中心(CDE)受理。公司亦在中國進行一項其用於治療RET+實體瘤的Ib/II期臨床研究。

2021年3月，本公司向總部設在英國的國際腫瘤藥物開發公司Ellipses Pharma Limited授出在大中華區及部分亞洲國家之外開發、製造及商業化此藥物的獨家授權。2024年4月，A400/EP0031獲美國食品藥品監督管理局(FDA)批准進入II期臨床研究(NCT05443126)，目前正在美國、英國、歐盟和阿聯酋入組患者，評估該藥物作為單藥及聯合化療在RET融合陽性NSCLC中的療效。

關於SKB500
SKB500是一款由公司針對靶點生物學特點，利用OptiDC™平臺技術研發的具有自主智慧財產權的新型ADC藥物，其採用了經驗證靶點與差異化的有效載荷－連接子策略。在前期研究中，SKB500顯示出良好的療效和安全窗，擬用於治療多種晚期實體瘤。目前，SKB500聯合免疫加與不加化療一線治療廣泛期小細胞肺癌(ES-SCLC)的聯合用藥探索II期研究正在中國進行中。

關於科倫博泰
四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC™，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。

SAN FRANCISCO and SUZHOU, China, April 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2^α-biased bispecific fusion protein) ^* as well as TYVYT® (sintilimab injection)^** will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026, in Chicago, Illinois, U.S.

Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, stated: "We are excited to announce that at the 2026 ASCO Annual Meeting, we will present new PoC data of IBI363 in NSCLC, across both IO-resistant and first-line settings. With robust PoC data for IO-resistant NSCLC now in hand, we are moving IBI363 into MRCT pivotal development, an important step toward tackling a major global unmet medical need. At the same time, we are encouraged by the promising dose optimization data in first-line NSCLC, and we look forward to continued maturation of PoC full data to inform our next steps. Innovent will continue to push the boundaries of cancer care, as we are dedicated to delivering physicians and patients more innovative, effective, and life-saving treatment options."

Abstracts of IBI363(PD-1/IL-2^α-biased bispecific fusion protein)

1.  Presentation Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC).
Abstract Number: 8586
Session Type: Poster
Session Title: Lung Cancer/Non-Small Cell Metastatic
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Haiyan Tu, Guangdong Provincial People's Hospital

2.  Presentation Title: First-in-class PD-1/IL-2^α-bias bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC): updated results from a phase I study.
Abstract Number: 2618
Session Type: Poster
Session Title: Developmental Therapeutics/Immunotherapy
Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Jianya Zhou, First Affiliated Hospital of Zhejiang University School of Medicine

3.  Presentation Title: Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO).
Abstract Number: TPS8673
Session Type: Poster
Session Title: Lung Cancer/Non-Small Cell Metastatic
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Roy S. Herbst, Yale School of Medicine

Abstracts of TYVYT®(sintilimab)

1.  Presentation Title: Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2)
Abstract Number: TPS4254
Session Type: Poster
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Yongjun Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine

2.  Presentation Title: Neoadjuvant chemoradiotherapy with or without PD-1 blockade in pMMR/MSS low rectal cancer patients (CHOICE II): A multi-center, open-label, randomized controlled trial.
Abstract Number: 3640
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Wei Zhang, Changhai Hospital

3.  Presentation Title: Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study 
Abstract Number: 4148
Session Type: Poster
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Jia Fan, Zhongshan Hospital, Fudan University

4.  Presentation Title: CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Abstract Number: TPS3680
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026, 9:00 AM-12:00 PM CDT
Presenter: Dr. Yue Liu, The Second Affiliated Hospital of Zhejiang University School of Medicine.

5.  Presentation Title: Long-term survival and biomarker analysis of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. 
Abstract Number: 3610
Session Type: Poster
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Xiao Weiwei, Sun Yat-sen University Cancer Center

6.  Presentation Title: Larynx preservation via chemotherapy-free neoadjuvant sintilimab-cetuximab-SBRT and response-adapted treatment in locally advanced laryngeal cancer: A phase II, single-arm clinical trial (The NeoVOICE study).
Abstract Number: 6095
Session Type: Poster
Session Title: Head and Neck Cancer
Session Date & Time: May 30, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Song Ming, Sun Yat-sen University Cancer Center

7.  Presentation Title: Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma.
Abstract Number: LBA4082
Session Type: Poster
Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date & Time: May 30, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Xuefeng Leng, Sichuan Cancer Hospital

8.  Presentation Title: Sintilimab (PD-1 antibody) Plus Gemcitabine and Docetaxel (GT) as First-line or Later-line Therapy in Patients with Advanced Epithelioid Sarcoma: A Prospective, Multicenter, Single-arm, Phase II Clinical Study.
Abstract Number: 11574
Session Type: Poster
Session Title: Sarcoma
Session Date & Time: June 1, 2026 1:30 PM-4:30 PM CDT
Presenter: Dr. Xiaowei Zhang, Fudan University Shanghai Cancer Center

9.  Presentation Title: Sintilimab plus Anlotinib and Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma: A Prospective, Phase II Clinical Trial.
Abstract Number: 8050
Session Type: Poster
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Date & Time: May 31, 2026 9:00 AM-12:00 PM CDT
Presenter: Dr. Jianchun Duan, Cancer Hospital, Chinese Academy of Medical Sciences

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

Amid investor concerns that the US and Iran may fail to reach a peace agreement before Wednesday's ceasefire deadline, US equities headed south following early gains on Tuesday. The DJIA ended the day down 293 points or 0.6% at 49,149. The S&P 500 declined 45 points or 0.6% to close at 7,064. The Nasdaq dropped 144 points or 0.6%, closing at 24,259.

UnitedHealth (UNH.US) crossed the finish line up 7%. It delivered forecast-beating results for 1Q26 and raised earnings guidance. Amazon (AMZN.US) inched 0.7% higher. It announced plans to invest up to an additional USD25 billion in AI company Anthropic. 3M (MMM.US) receded 2% post-results. It maintained its full-year earnings guidance unchanged.
~



AAStocks Financial News
Web Site: www.aastocks.com

BEIJING, April 22, 2026 /PRNewswire/ -- CATL today hosted its Super Technology Day in Beijing, unveiling third-generation Shenxing Superfast Charging Battery, third-generation Qilin Battery, Qilin Condensed Battery, second-generation Freevoy Super Hybrid Battery, Naxtra Sodium-ion Battery and a fully integrated supercharging and battery-swapping solution. These innovations are designed to address diverse mobility needs across different usage scenarios.

At the event, Dr. Wu Kai, Chief Scientist of CATL, systematically elaborated on the respective strengths, limitations, and development pathways of different chemistries. He noted that LFP is nearing its theoretical energy density limit, making it better suited for a technology roadmap centered on extreme fast charging to achieve optimal balance. NCM's high energy density keeps it at the forefront of global competition — underscoring that energy density remains the core metric for leadership. Sodium-ion batteries offer broad potential for extreme temperatures and energy storage applications. Whether from the perspective of differentiated consumer needs, or from the viewpoints of energy security and social development, the lithium-ion battery industry must pursue coordinated development across multiple chemical systems.

Robin Zeng, Chairman and CEO of CATL, emphasized at the conference that industrial innovation must be driven by a rigorous scientific spirit. For Chinese technology to go global, it relies not just on speed and scale, but on the quality of innovation, the ability to validate, and the credibility of the brand.

Third-Generation Shenxing Superfast Charging Battery: Making Superfast Charging and Ultra-Long Lifespan No Longer a Trade-Off

From an electrochemical standpoint, boosting charge rates while protecting battery lifespan hinges on one primary factor: temperature rise, not trickle current. As the Arrhenius equation shows, a 10°C increase in battery temperature can roughly double the rate of internal side reactions—an effect that can significantly shorten cycle life.

The third-generation Shenxing Superfast Charging Battery addresses heat generation and dissipation through three major measures: reduced heat production during operation, stronger thermal propagation, and higher precision control. As a result, after 1,000 complete cycles, the battery's capacity retention remains above 90%, achieving an optimal balance between extreme superfast charging and ultra-long service life.

The latest third-generation Shenxing Superfast Charging Battery has reached what is claimed to be the industry's strongest capability: an equivalent 10C and a peak 15C charging rate. Charging from 10% to 35% SOC (State of Charge) takes just 1 minute; from 10% to 80% SOC takes 3 minutes and 44 seconds; and from 10% to 98% SOC takes 6 minutes and 27 seconds. Even at −30°C in extreme cold conditions, charging from 20% to 98% SOC takes about 9 minutes.

In addition, by combining battery self-heating technology with a fully integrated supercharging and battery-swapping network, the system is designed to enable low-temperature superfast charging that is not limited by charging piles—offering both fast charging and battery swapping.

Third-generation Qilin Battery: Lighter, Stronger, More Premium, Redefining EV Excellence

Historically, achieving long range in premium EVs with LFP batteries has relied on simply adding more capacity — an approach that inevitably compromises vehicle lightweighting.

The third-generation Qilin Battery is designed for premium long-range EVs, achieving a cell energy density of 280 Wh/kg and enabling 1,000 km range while supporting 10C superfast charging.

The battery delivers 3 MW peak power, doubling the output of the second-generation Qilin track battery which competed on the Nürburgring (1,330 kW).

The entire battery pack weighs only 625 kg. Compared with equivalent LFP systems, this represents a weight reduction of 255 kg and space savings of 112 litres. The lightweighting metrics deliver exceptionally significant benefits:

• Energy consumption per 100 km decreases by more than 6%, saving approximately 0.78 kWh per 100 km. Across a fleet of one million vehicles travelling 20,000 km annually, this equates to 156 million kWh in electricity savings and a reduction of 78,500 tonnes of CO₂ emissions.
• Performance and safety improvements include a 0.6–second reduction in 0–100 km/h acceleration, a 12% shorter overtaking risk window, an 8% higher moose test speed, a 6.5% lower body roll angle, a 15–25% gain in obstacle avoidance capability, and approximately 1.44 metres shorter braking distance.
• Durability is enhanced, with chassis component life extended by 40% and tyre life by over 30%, increasing replacement intervals by at least 10,000 km. The 112 litres of space saved can increase cabin headroom by at least 18 mm.

Building on the national standard for NP (No Thermal Propagation), safety is strengthened through "thermal-electrical separation", with each cell incorporating an independent sealed exhaust channel to isolate thermal events and prevent propagation, ensuring "heat takes the heat path, electricity takes the electrical path". 

Qilin Condensed Battery: Aviation-Grade Technology Applied to Passenger Vehicles for the First Time

The Qilin Condensed Battery applies aviation-grade technology to passenger vehicles for the first time, achieving 350 Wh/kg cell energy density and 760 Wh/L volumetric energy density — setting a new record for mass-produced batteries. This enables 1,500 km range for sedans and over 1,000 km for large SUVs, with pack weight controlled within 650 kg.

The condensed battery features a high-nickel cathode and low-expansion silicon-carbon anode, boosting energy density by 50 Wh/kg. Its first-ever aviation-grade titanium alloy case reduced thickness by 60% and weight by 30%, while tripling unit strength and delivering an additional 20 Wh/kg in energy density.

The technology builds on CATL's electric aviation programme, where 500 Wh/kg systems have completed maiden flight validation on 4-tonne aircraft, with further validation underway on aircraft exceeding 8 tonnes.

Replacing liquid electrolyte with a condensed system eliminates risks associated with leakage and combustion, achieving "no liquid to leak, no liquid to ignite". At the same time, CATL has adopted a new composite current collector that acts as a fast self-fusing fuse in extreme cases of internal short circuits.

Second-generation Freevoy Super Hybrid Battery: Bringing Hybrids into the 600 km Pure Electric Era

The second-generation Freevoy Super Hybrid Battery extends all-electric range to up to 600 km and standardises 10C superfast charging. It pioneers a "super hybrid technology" that integrates LFP and NCM materials through gradient-uniform mixing, with the olivine crystal structure of LFP serving as the core backbone, enabling a uniform hybrid of LFP and NCM materials at the powder particle level.

This achieves an energy density of 230 Wh/kg and increases range by over 15% without increasing pack weight compared with single LFP systems. This enables full coverage from mainstream family use to high-end, all-round hybrid scenarios, delivering optimal solutions across diverse applications.

The LFP version delivers up to 500 km pure electric range, enabling a "once-a-week charging" experience for daily commuting. The NCM version further extends pure electric range beyond 600 km, with total vehicle range exceeding 2,000 km, enabling a seamless dual-use experience for both daily electric driving and long-distance travel.

The system delivers 1.5 MW of instantaneous power at full charge and maintains 1.2 MW at 20% SOC, addressing power degradation in low-charge conditions. In off-road scenarios requiring over 350 kW output, the system provides more than three times the required power, ensuring consistent performance even at low charge levels.

Safety features include a reinforced bottom coating capable of withstanding 1,500 joules of impact energy (ten times the national standard) and waterproof sealing that allows continuous immersion in 2 metres of water for over 200 hours without performance degradation.

Naxtra Sodium-ion Battery: Achieving GWh-scale Sodium-ion Industrialisation

The Naxtra Sodium-ion Battery marks CATL's transition from laboratory breakthrough to large-scale manufacturing. By systematically overcoming hundreds of engineering challenges, CATL has achieved GWh-level industrialisation.

In 2026, CATL successfully addressed four key industry bottlenecks for sodium-ion mass production—extreme water control, gas generation in hard carbon, aluminium foil adhesion, and self-forming anode systems—paving the way for reliable, large-scale deployment. The Naxtra Sodium-ion Battery is set to enter full-scale mass production by the end of 2026.

Integrated Supercharging and Battery-swapping Network: A Unified Replenishment Architecture

CATL also introduced an integrated supercharging and battery-swapping network, designed as a unified system rather than separate solutions, built on three complementary pillars—home charging, public charging, and battery swapping—to define the optimal energy replenishment ecosystem. All passenger vehicle "Choco-Swap" and heavy truck "QIJI" swapping stations will be equipped with Shenxing supercharging systems, enabling true charge–swap synergy, where each station serves both as a battery-swapping node and a high-power charging hub.

The integrated charge–swap stations feature shared compact substations and charging modules, reducing energy conversion steps and lowering overall power loss by more than 13 percentage points compared with conventional storage-equipped charging stations. In emergency scenarios, station batteries can discharge directly to charging piles, driving equipment utilization rate above 85%. This enables a service capacity of 3× per parking space compared with conventional storage-equipped charging stations, while the fixed investment cost of the supercharging segment is reduced to only one-fifth of comparable systems.

CATL launched the Choco-Swap #26 battery, featuring an 800V high-voltage architecture. The first release includes a 75 kWh version, with higher-capacity variants to follow, fully compatible with B- to C-segment 800V vehicles. With this launch, the Choco-Swap system will extend its coverage to a complete vehicle matrix from A0 to C-segment models.

In terms of network deployment, CATL plans to build 4,000 integrated charge–swap stations by the end of 2026, covering nearly 190 cities and a nationwide highway network spanning 12 vertical and 11 horizontal corridors. To date, the Choco-Swap network has already built 1,470 stations across 99 cities, with scaling continuing to accelerate.

Together with automakers and energy partners, CATL will co-develop a "charge–swap sharing network" based on technology sharing, seamless connectivity, and joint investment. Initial partners include Changan, Chery, GAC, Seres, SAIC-GM-Wuling, and BAIC, with a target of building over 100,000 shared energy replenishment facilities by the end of 2028.

Advancing full-scenario energy solutions

From five battery products covering the full material spectrum to an integrated supercharging and battery-swapping network, CATL has established a complete value chain from battery products to infrastructure.

CATL will continue to invest in advanced research, large-scale manufacturing and ecosystem collaboration to accelerate the transition from single-point innovation to full-scenario energy solutions, ensuring the benefits of technological progress are accessible across all mobility use cases.

HONG KONG and NINGBO, China, April 21, 2026 /PRNewswire/ -- Joyson Electronics (0699.HK) has, for the first time, released two sustainability-related reports in tandem—its Sustainability Report 2025 and Nature-related Disclosures Report 2025. It continues to embed sustainability into its strategy and long-term development.

During the year 2025, Joyson achieved solid progress across technology innovation, green manufacturing, and corporate social responsibility, and joined both the United Nations Global Compact (UNGC) and the Responsible Business Alliance (RBA)—helping drive the industry toward a greener and more prosperous future.

Riding the momentum of vehicle electrification and intelligent mobility, Joyson invested approximately RMB4.4 billion in forward-looking R&D in 2025. It remains committed to its "multi-chip platforms + ecosystem partnerships" technology roadmap, continuously advancing L3/L4 advanced driver assistance and autonomous driving capabilities, with multiple high-quality orders set to enter mass production starting 2026.

Beyond improving mobility efficiency and reducing emissions through intelligent technologies, Joyson Electronics also continues to roll out high-voltage, low-loss new energy management solutions, supporting greener mobility worldwide.

Basing on strong technology synergies, Joyson is further extending these capabilities into robotics components and server infrastructure, creating new growth engines. Joyson has launched a portfolio of products for robots, including central controllers, energy management and "limb" systems. And it is working with leading customers both in China and overseas.

In addition, Joyson has debuted an automotive optical module co-developed with Zhongji Innolight and is accelerating global commercialization of optical module technologies through investments that expand North American production capacity. Over the same period, the Company has also expanded its automotive-grade power electronics into industrial server power supply applications.

During the reporting period, Joyson Electronics used nearly 250,000 MWh of renewable energy—up 27% from 2024—avoiding over 100,000 tonnes of CO₂e emissions. Joyson is targeting carbon neutrality in core operations by 2040, and has also set goals—using 2024 as the baseline year—to strive for a 6% reduction in both water intensity and waste generation intensity by 2030.

Joyson stated that it will continue to fully integrate ESG into its strategy and operational management, further strengthening its ESG management system and creating a more prosperous and sustainable future for society.

About Joyson Electronics

Joyson Electronics (600699.SH / 699.HK) is a leading global provider of smart technology solutions, specializing in the R&D and manufacturing of automotive electronics, automotive safety systems, and key components for robots. Joyson operates more than 25 R&D centers and 60 production facilities, and serves over 100 global automotive brands. Revenue reached RMB 61.2 billion in 2025.

Joyson Electronics positions itself as a "Tier 1 supplier for automotive and robotics," providing customers with innovative products in the fields of autonomous driving, intelligent cockpits, car connectivity, E-Mobility, automotive safety, and key robotics components. It is a leading global supplier of autonomous driving, with its full-stack solutions supporting multi-scenario autonomous driving capabilities from Level 2 to Level 4. Joyson is also the second-largest supplier of intelligent cockpit domain control systems in China and the fourth largest globally.

Additionally, Joyson Electronics has supplied samples or products to robotics companies worldwide, establishing itself as a leader in the embodied intelligent robotics components industry.

香港和寧波2026年4月21日 /美通社/ -- 均勝電子（699）首次同步發佈《2025年度可持續發展報告》和《2025年度自然相關資訊披露報告》。公司將可持續發展理念融入戰略與長遠發展，舊年在技術創新、綠色製造、社會責任踐行等方面成效顯著。公司亦已加入聯合國全球契約組織及責任商業聯盟，持續引領行業邁向更加綠色、繁榮的未來。

順應汽車智能、電動趨勢，均勝電子2025年投入約44.2億元加碼前瞻技術研發。公司堅持「多芯片+生態合作」技術路線，持續迭代L3/L4高級輔助駕駛功能，多個高品質訂單將於今年起陸續量產。除了通過智能技術直接提高出行效率、減少碳排放，均勝還持續推出高壓、低損的新能源管理方案，推動全球綠色出行。

基於技術同源性，均勝電子還將上述技術延展至機械人、服務器基建等產業，打造增長新引擎。公司已發佈「大小腦、能源管理、肢體」等機械人相關產品，與海內外頭部客戶合作。同時，公司還首發與中際旭創聯合開發的車載光模塊產品，並透過投資新菲光北美產能來推進光模塊技術全球商用。同期，均勝還將車規級電源相關產品拓展至工業級服務器電源領域。

值得一提的是，均勝電子去年加入聯合國全球契約組織（UNGC），承諾履行《全球契約十項原則》。公司也是國內首家汽車零部件行業自然相關財務資訊披露工作組（TNFD）支持者，助力聯合國實現可持續發展目標（SDGs）。期內，公司還正式加入負責任商業聯盟（RBA）及負責任礦產倡議（RMI）。

憑藉持續優化的ESG表現，公司已連續兩年入選標普全球《可持續發展年鑒（中國版）》，並榮獲行業最佳進步企業。同時，公司在CDP氣候變化、森林與水等主題獲得積極評價，並獲得EcoVadis銀牌等協力廠商認可；入選2024-2025年度福布斯中國可持續發展工業企業榜。

長期以來，均勝電子將綠色理念融入全球據點的運營與供應鏈管理，並以品質管控和低碳清潔生產夯實核心競爭力。報告期內，公司可再生能源使用近25萬MWh，較2024年增長27%，避免超10萬噸二氧化碳當量排放。均勝將力爭於2040年實現核心運營碳中和，亦設定以2024年為基準年，到2030年取力爭實現取水強度、廢棄物產生強度均實現降低6%的目標。

均勝電子錶示，未來繼續將ESG治理全面融入公司戰略和經營管理，構建ESG管理體系，為社會創造更加繁榮和可持續的未來。

關於均勝電子

均勝電子（600699.SH / 699.HK）是全球領先的智能科技解決方案提供商，專注於汽車電子、汽車安全及機械人關鍵部件的研發與製造。公司全球設有超過 25 個研發中心和 60 個生產基地，客戶覆蓋超 100 個全球汽車品牌。2025年營業收入達人民幣 612 億元。

均勝電子定位「汽車 + 機械人Tier1」，向客戶提供智能駕駛、智能座艙、智能網聯、新能源管理、汽車安全以及機械人關鍵部件領域的創新產品。公司是全球智能駕駛頭部供應商，其全棧解決方案可支持實現 L2 到 L4 級別的多場景自動駕駛功能；公司也是中國第二、全球第四大智能座艙域控系統供應商。此外，均勝電子亦已向國內外知名機械人公司送樣或供貨，是全球具身智能機械人部件行業的領先者。

HONG KONG, April 21, 2026 /PRNewswire/ -- Newborn Town, a leading global social entertainment company, announced the launch of its AI Agent Pay project, NUSD Pay, marking its strategic move into autonomous payment infrastructure for AI Agents.

As a global technology company with deep roots in overseas markets, Newborn Town's products and services cover multiple regions, including MENA, Southeast Asia, Latin America, and Europe, supported by a broad and diversified global user base. Across its global operations, the efficiency of cross-border fund flows and settlement has always been a critical infrastructure capability.

In the second half of 2025, Newborn Town officially initiated the NUSD Pay project. The core system has now been completed and entered commercial operation. Compared with traditional cross-border payment solutions, NUSD Pay is able to reduce overall transaction costs by more than 70%, delivering a more efficient, secure, and seamless payment and settlement experience for global merchants.

From current industry practices, the application of AI Agent Pay is rapidly expanding across multiple scenarios, including API usage billing, data and content access, and computing resource allocation, and is expected to gradually evolve into the next generation of digital payment infrastructure.

NUSD Pay is currently developing its AI Agent payment product based on the x402 protocol. The x402 protocol moves payment capabilities from the traditional application layer down to the HTTP protocol layer. Its core mechanism leverages the HTTP 402 Payment Required status code to trigger payment flows, creating a standardized framework for machine-to-machine transactions.

Through this protocol, when AI Agents call services or execute tasks, they can automatically complete payment settlement just like making an API request—without requiring manual authorization for each transaction—enabling seamless autonomous transactions between machines.

At present, NUSD Pay has completed the initial deployment of AI Skills on the OpenClaw platform, allowing users to access product information and API development documentation for NUSD Pay through natural language interaction.

According to the project lead, the company plans to gradually expand these capabilities in the future, including data inquiries, automated reconciliation, wallet address creation, and backend management functions, further lowering the barriers for enterprise clients to integrate payment systems.

NUSD Pay will first serve Newborn Town's own global business ecosystem, while also launching enterprise-level payment solutions for B-end clients. Regarding the rationale behind entering the AI Agent Pay business, the person in charge stated that the move is primarily driven by the long-term development needs of the company's global operations.

"The launch of NUSD Pay represents a long-term strategic exploration by the company amid the evolution of global payment technologies. As AI technology continues to advance, an increasing number of commercial activities may eventually be completed autonomously by AI systems. The business is still at an early stage, and we will continue to closely monitor the development of AI Agent payment trends, while actively exploring related technologies and application scenarios within a compliant framework."

• RoboSense debuted the EOCENE SPAD-SoC architecture, enabling rapid incubation of a diverse chipset portfolio while streamlining R&D workflows to deliver significant structural cost advantages.
• RoboSense launched the Phoenix chipset, the industry's first automotive-grade monolithic SPAD-SoC, delivering 2,160-beam image-grade output to establish a new benchmark for high-definition 3D perception.
• RoboSense introduced the Peacock chipset, a fully solid-state, ultra-large array SPAD-SoC, propelling robotics into the era of image-grade 3D perception
• RoboSense's RGBD sensor is slated for official release by the end of 2027

SHENZHEN, China, April 21, 2026 /PRNewswire/ -- RoboSense (HKEX: 2498), an AI-driven robotics technology company, hosted its 2026 Tech Day in Shenzhen today, marking a landmark moment with the global debut of its pioneering self-developed SPAD-SoC architecture, EOCENE, and two flagship image-grade chipsets, Phoenix and Peacock. Alongside these core launches, RoboSense offered a strategic preview of its revolutionary RGBD sensor, slated for release in 2027. This breakthrough signifies a paradigm shift in 3D perception technology, solidifying RoboSense's position as the architect of the industry's next technological cycle, and an insightful visionary poised to capture the expansive market potential now unfolding.

Mark Qiu, CEO of RoboSense, remarked: "Drawing a strategic parallel to the historic transition from CCD to CMOS within the imaging industry, we believe the LiDAR sector has reached a critical inflection point. By establishing our proprietary SPAD-SoC architecture as the foundation, we are redefining the metrics of 3D perception. In our view, mastery of chipset capability is the ultimate arbiter of generational advantage. Those who command the silicon effectively wield control over product generational evolution, securing a privileged position and holding the high ground in the future industry landscape."

RoboSense's overarching strategy centers on the vertical integration of proprietary chipset R&D and advanced module engineering. Securing a dominant position in the coming stage of large-scale commercialization requires a full-stack approach: proprietary chipset capabilities establish technological generational leads and structural cost advantages, while module engineering ensures system-level excellence in point-cloud fidelity, ranging precision, and interference rejection. By integrating these twin engines, RoboSense is establishing the definitive performance benchmarks for the next phase of industrial evolution of 3D perception.

The Visionary Trend of LiDAR Industry Evolution

The shift from analog to digital architectures is an industry imperative. Mirroring the historic pivot from CCD to CMOS in the imaging sector, RoboSense recognizes that the LiDAR industry has reached its definitive "CMOS moment." Legacy analog architectures have hit inherent performance ceilings, where further scaling triggers prohibitive complexity and linear cost escalation. In the LiDAR sector, analog solutions—epitomized by SiPM—are destined to be superseded by SPAD architectures, much like the transition that once rendered CCD obsolete. Furthermore, sharing the same semiconductor lineage as CMOS, SPAD technology capitalizes on Moore's Law, enabling direct access to the mature process nodes and infrastructure of the global semiconductor ecosystem.

The evolution toward high-beam, image-grade performance is equally irreversible. Under the SPAD architecture, the performance ceiling of LiDAR has been significantly elevated, dramatically enhancing detection capabilities for small objects at long ranges and ensuring robustness in adverse weather. By reaching 2160 beams, LiDAR enters the 4-megapixel era; as it scales further to 4000 beams, it achieves an 8-megapixel output, meeting the true 4K standard. This transition into the image-grade era will fundamentally redefine safety standards—positioning high-resolution LiDAR as a non-negotiable safeguard for both L2+ and L3 autonomous vehicles.

EOCENE：The SPAD-SoC Platform

RoboSense introduced its groundbreaking SPAD-SoC architecture, the EOCENE. Named after the dawn of a new era, the platform marks a fundamental transition from discrete technical breakthroughs to a scalable production model. By codifying nine years of full-stack experience into a standardized R&D paradigm, EOCENE enables the rapid incubation of a high-performance SoC portfolio, establishing a systematic competitive barrier through efficient innovation.

The EOCENE SPAD-SoC architecture is designed with 4 Core Functional Layers:

• Fundamental Process Layer: Unified 28nm advanced process node with automotive-grade design; features 3rd-Gen ultra-sensitivity SPAD with a world-leading 45% PDE and 2nd-Gen 3D-stacking via wafer-level hybrid bonding.

• Core Computational Layer: Configurable 4320-Core heterogeneous compute Array; powered by a high-bandwidth network-on-chip (NoC) supporting 495 billion point-cloud samplings/s and an up to thousand-beam ultra-HD perception enhancement engine.

• Algorithm Acceleration Layer: hardware-integrated anti-Interference & signal processing engine; delivers up to 99.9% sunlight noise suppression and 99.9% crosstalk immunity with smart pixel management for optimized perception.

• Security & Reliability Layer: Automotive-grade secure silicon architecture; strictly engineered for extreme reliability and operational resilience across a temperature range of -40°C to 125°C.

The Phoenix Chipsets

RoboSense unveiled Phoenix, an automotive-grade monolithic SPAD-SoC capable of 2,160-beam image-grade output. The Phoenix series will feature a versatile lineup of five distinct models, specifically engineered to support LiDAR designs spanning 2160, 1440, 720, 480, and 240 beams. Compared to designs that cluster or cascade multiple chips to achieve high beam counts, Phoenix delivers true 2160-beam performance independently through a streamlined, single-optical path. This state-of-the-art monolithic integration enables an ultra-high resolution of 2160 × 1900—surpassing the point-cloud fidelity of a 4MP camera—and outputs 2K ultra-HD near-infrared (NIR) imagery. With a 600-meter detection range and AEC-Q100 certification, Phoenix evolves LiDAR from a basic ranging sensor into a sophisticated visual imaging system. The 2,160-beam solution based on Phoenix have already secured design wins from world-leading automakers, with mass production scheduled in 2026. 

The Peacock Chipset

RoboSense unveiled Peacock, a premier all-solid-state ultra-large array SPAD-SoC featuring a high-density resolution of 640 × 480, propelling robotics into the era of image-grade 3D perception. By integrating this massive matrix into a single SoC, Peacock shifts LiDAR output from sparse data points to VGA-level imaging output. The chipset provides an expansive 180° × 135° field of view (FOV) and millimeter-level precision, capable of detecting objects as close as 5cm. Designed for broad cross-industry adoption, Peacock's versatile architecture seamlessly adapts to diverse applications—from automotive blind-spot detection and low-speed autonomous vehicles to industrial safety, robotics, and emerging super-sensor form factors. Peacock is slated for mass production in Q3 2026, with initial batch deliveries already underway to key customers.

RGBD: Advancing Spatial Intelligence with Color-Enriched 3D Imaging

By integrating a color filter array with the high-resolution output of the Peacock chipset, RoboSense has achieved advanced RGBD (Red, Green, Blue + Depth) 3D vision. The core of this innovation is Peacock's ability to output high-density spatial data, which allows the seamless integration of color information directly onto 3D point clouds.

RoboSense has long been a pioneer in the exploration of sensor fusion. The introduction of the AC1 and AC2 Active Camera series in 2025 provided the industry with a diverse range of integrated perception solutions, laying the essential groundwork for advancing colorized 3D vision. RoboSense's new RGBD sensor is slated for official release by the end of 2027.

Looking ahead, RoboSense is committed to ushering in an era where 3D perception achieves the same ubiquity as the modern camera. By integrating its visionary technology into every vehicle, every robot, and every physical AI terminal, RoboSense is not merely participating in a technological shift—it is standing as the definitive architect of a new epoch in 3D perception.

Please access the full press kit via the link:
https://www.dropbox.com/scl/fo/zafeavobmdke8cp0mgmtt/AKduk648136gxk3w9moF87o?rlkey=5n0n2843o5hpvqgm0fxmi2q9t&st=nagfu804&dl=0

About RoboSense

RoboSense (02498 HKEX) is an AI-driven robotics company, founded in 2014 and headquartered in Shenzhen, China. Leveraging its full-stack, in-house developed digital chips and a robust AI technology system, the company provides core robotic components, perception systems, and manipulation solutions across a wide range of industries, including autonomous passenger and commercial vehicles, Robotaxi, as well as robotics applications in autonomous logistics, robotic lawn mowers, and humanoid robots.

As a global leader in the LiDAR industry, RoboSense has partnered with over 310 automotive brands and Tier-1 suppliers. In the robotics sector, it is the preferred solution provider for autonomous logistics, robotic lawn mowers, humanoid robots, and other pan-robotics applications, serving more than 3,400 clients worldwide. In 2025, the company ranked first in LiDAR market share in the robotics sector.

Building on its globally leading perception capabilities, RoboSense has extended its technology into robotic manipulation, launching robotic vision systems, dexterous hands, and hand-eye coordination solutions, driving the large-scale commercialization in the era of Physical AI.